Published in Int J Dent Hyg on April 24, 2013
Orofacial manifestations of systemic sclerosis. Br Dent J (2016) 0.89
Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III. Arthritis Care Res (Hoboken) (2015) 0.82
Factors associated with oral hygiene practices among adults with systemic sclerosis. Int J Dent Hyg (2013) 0.80
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand (1963) 15.52
EXPERIMENTAL GINGIVITIS IN MAN. J Periodontol (1965) 7.13
Xerostomia: etiology, recognition and treatment. J Am Dent Assoc (2003) 2.61
Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc (1987) 2.35
Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum (2001) 1.87
A method for evaluating oral hygiene performance. Public Health Rep (1968) 1.86
Scleroderma epidemiology. Rheum Dis Clin North Am (2003) 1.70
Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol (2011) 1.61
Comparison of the effects of cetylpyridinium chloride with an essential oil mouth rinse on dental plaque and gingivitis - a six-month randomized controlled clinical trial. J Clin Periodontol (2007) 1.57
Analysis of the oral manifestations of systemic sclerosis (scleroderma). Oral Surg Oral Med Oral Pathol (1988) 1.45
Xerostomia. A neglected symptom. Arch Intern Med (1987) 1.29
Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev (2003) 1.23
Small mouths ... Big problems? A review of scleroderma and its oral health implications. J Can Dent Assoc (2007) 1.20
Study design for calibration of clinical examiners measuring periodontal parameters. J Periodontol (2006) 1.15
Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum (1997) 1.14
Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum (2006) 1.14
A comparison of three methods of measuring maximal opening of the mouth. J Oral Surg (1979) 1.12
Scleroderma: oral manifestations. Oral Surg Oral Med Oral Pathol (1981) 1.12
Recommendations for the care of oral involvement in patients with systemic sclerosis. Arthritis Care Res (Hoboken) (2011) 1.10
Dental erosion and acid reflux disease. Ann Intern Med (1995) 1.10
Racial differences in scleroderma among women in Michigan. Arthritis Rheum (1997) 1.10
Profile of systemic sclerosis in a tertiary care center in North India. Indian J Dermatol Venereol Leprol (2006) 1.10
Factors related to oral hygiene in persons with scleroderma. Int J Dent Hyg (2005) 1.02
Modulation of clinical expression of plaque-induced gingivitis. II. Identification of "high-responder" and "low-responder" subjects. J Clin Periodontol (2004) 1.01
The nonsurgical treatment of microstomia in scleroderma: a pilot study. Oral Surg Oral Med Oral Pathol (1984) 0.97
Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Ann Rheum Dis (2007) 0.95
Daily activities and hand function in women with scleroderma. Scand J Rheumatol (2004) 0.94
Systemic sclerosis: description and diagnostic role of the oral phenomena. Gen Dent (2004) 0.93
Drugs and the periodontium. J Clin Periodontol (1988) 0.93
Oral health of Chinese people with systemic sclerosis. Clin Oral Investig (2010) 0.93
Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol (2009) 0.93
Effect of orofacial exercises on oral aperture in adults with systemic sclerosis. Disabil Rehabil (2011) 0.92
Sjogren's syndrome is associated with and not secondary to systemic sclerosis. Rheumatology (Oxford) (2006) 0.92
Cutaneous concerns of scleroderma patients. J Dermatol (2003) 0.87
Periodontal microcirculatory abnormalities in patients with systemic sclerosis. J Periodontol (2005) 0.87
Oral and gingival changes in systemic sclerosis (scleroderma). J Periodontol (1984) 0.87
Salivary glucose clearance, dry mouth and pH changes in dental plaque in man. Arch Oral Biol (1988) 0.87
Systemic sclerosis. Case report and review of literature. N Y State Dent J (2010) 0.86
Scleroderma: oral manifestations and treatment challenges. Spec Care Dentist (2008) 0.85
Prevalence of sicca symptoms in a South Australian cohort with systemic sclerosis. Intern Med J (2008) 0.83
Periodontal Status of Adults With Systemic Sclerosis: Case-Control Study. J Periodontol (2011) 0.81
The immunohistochemical analysis of vascular endothelial growth factors A and C and microvessel density in gingival tissues of systemic sclerosis patients: their possible effects on gingival inflammation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 0.81
Grasp pattern variations seen in the scleroderma hand. Am J Occup Ther (1994) 0.81
Rehabilitation in joint and connective tissue diseases. 1. Systemic diseases. Arch Phys Med Rehabil (1995) 0.80
The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis. J Rheumatol (2006) 0.80
Use of a water flosser for interdental cleaning. Compend Contin Educ Dent (2011) 0.80
Dexterity testing as a predictor of oral care ability. J Am Geriatr Soc (1994) 0.78
Testing toothbrushing ability of elderly patients. Spec Care Dentist (1995) 0.78
Hand dysfunction in scleroderma patients. Sao Paulo Med J (2011) 0.77
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science (1992) 3.71
The surveillance complex interacts with the translation release factors to enhance termination and degrade aberrant mRNAs. Genes Dev (1998) 3.71
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Optimal management strategies for placenta accreta. BJOG (2009) 3.51
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest (1985) 3.41
Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A (1993) 3.40
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis (1996) 2.93
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis (2009) 2.76
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med (1991) 2.68
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Purification and characterization of the Upf1 protein: a factor involved in translation and mRNA degradation. RNA (1995) 2.57
Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol (1995) 2.37
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med (1989) 2.30
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
Anomalous origin of the left coronary artery from the pulmonary artery in adults. J Card Surg (1995) 2.16
Using aortic allograft material to treat mycotic aneurysms of the thoracic aorta. Ann Thorac Surg (1996) 2.14
CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity (1996) 2.11
Scleroderma following augmentation mammoplasty. Report of a case and review of the literature. Arch Dermatol (1990) 2.08
Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp Med (1998) 2.06
Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res (2000) 1.98
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg (1986) 1.93
Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun (1996) 1.93
rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin Diagn Lab Immunol (1998) 1.90
Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis (1987) 1.87
P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol (2001) 1.86
Murine thymocytes proliferate in direct response to interleukin-7. Blood (1989) 1.86
Incidence of atrial flutter/fibrillation in adults with atrial septal defect before and after surgery. Ann Thorac Surg (1999) 1.84
Surgical treatment of active infective aortic valve endocarditis with associated periannular abscess--11 year results. Eur Heart J (2000) 1.82
Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. Ann Thorac Surg (1998) 1.82
A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med (1995) 1.81
T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol (2000) 1.76
Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A (1993) 1.76
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn (2001) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol (2000) 1.66
Immunopathology of experimental cutaneous leishmaniasis. Am J Pathol (1984) 1.65
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A (1995) 1.61
Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med (2000) 1.60
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun (1999) 1.55
Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol (2001) 1.54
Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report. Braz J Infect Dis (2001) 1.54
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun (1998) 1.53
Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem (2001) 1.52
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun (2001) 1.51
Correction of complete atrioventricular septal defects with the double-patch technique and cleft closure. Ann Thorac Surg (1996) 1.51
Regulation of T cell proliferation by IL-7. J Immunol (1990) 1.50
A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum (1989) 1.47
IL-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages. J Immunol (1994) 1.46
Is occupational organic solvent exposure a risk factor for scleroderma? Arthritis Rheum (1998) 1.45
Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2. J Immunol (1984) 1.45
Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis. J Clin Microbiol (2000) 1.44
A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis (1998) 1.43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg (1997) 1.43
Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J Immunol (1998) 1.38
Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol (1995) 1.38
Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol (1999) 1.38
Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg (1990) 1.37
Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients. J Exp Med (1992) 1.37
Heterologous antibody responses in mice with chronic T. cruzi infection: depressed T helper function restored with supernatants containing interleukin 2. J Immunol (1984) 1.35
Identification and synthesis of a major conserved antigenic epitope of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1992) 1.34
Anomalous origin of the left coronary artery from the pulmonary artery. Early results with direct aortic reimplantation. J Thorac Cardiovasc Surg (1994) 1.33
Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species. Am J Trop Med Hyg (1983) 1.32
Identification of specific and cross-reactive antigens of Leishmania donovani chagasi by human infection sera. J Immunol (1987) 1.32
LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol (1998) 1.31
Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. J Immunol (2000) 1.31
A quantitative MR study of the hippocampal formation, the amygdala, and the temporal horn of the lateral ventricle in healthy subjects 40 to 90 years of age. AJNR Am J Neuroradiol (1999) 1.30
Suppression of cell-mediated immunity in experimental Chagas' disease. Z Parasitenkd (1977) 1.30
Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med (2001) 1.29
Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis. Infect Immun (1998) 1.28
A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J Biol Chem (1999) 1.28
Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans R Soc Trop Med Hyg (1995) 1.27
A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera. J Infect Dis (1999) 1.25
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun (2002) 1.25
Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol (1996) 1.24
Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg (1986) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol (1992) 1.21
A secreted and LIF-mediated stromal cell-derived activity that promotes ex vivo expansion of human hematopoietic stem cells. Blood (2000) 1.20
Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun (1995) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol (1998) 1.19
Spleen cell-mediated suppression of IgG production to a non-parasite antigen during chronic Trypanosoma cruzi infection in mice. J Immunol (1983) 1.18
Surgical outcome after removal of idiopathic macular epiretinal membrane in young patients. Eye (Lond) (2007) 1.18
Molecular karyotype of species and subspecies of Leishmania. Mol Biochem Parasitol (1986) 1.17
Bridging-to-recovery. Ann Thorac Surg (2001) 1.16
Genetic tuning of the novel avian influenza A(H7N9) virus during interspecies transmission, China, 2013. Euro Surveill (2014) 1.16
Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol (2001) 1.16
Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen. J Clin Microbiol (2001) 1.15
Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species. J Infect Dis (1993) 1.15